ENTA
Price
$7.20
Change
+$0.09 (+1.27%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
153.91M
67 days until earnings call
KRYS
Price
$132.73
Change
+$0.70 (+0.53%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
3.84B
67 days until earnings call
Interact to see
Advertisement

ENTA vs KRYS

Header iconENTA vs KRYS Comparison
Open Charts ENTA vs KRYSBanner chart's image
Enanta Pharmaceuticals
Price$7.20
Change+$0.09 (+1.27%)
Volume$5.49K
Capitalization153.91M
Krystal Biotech
Price$132.73
Change+$0.70 (+0.53%)
Volume$6.21K
Capitalization3.84B
ENTA vs KRYS Comparison Chart
Loading...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTA vs. KRYS commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a Buy and KRYS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ENTA: $7.20 vs. KRYS: $132.73)
Brand notoriety: ENTA and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 53% vs. KRYS: 65%
Market capitalization -- ENTA: $153.91M vs. KRYS: $3.84B
ENTA [@Biotechnology] is valued at $153.91M. KRYS’s [@Biotechnology] market capitalization is $3.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whileKRYS’s FA Score has 0 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • KRYS’s FA Score: 0 green, 5 red.
According to our system of comparison, both ENTA and KRYS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 6 TA indicator(s) are bullish while KRYS’s TA Score has 6 bullish TA indicator(s).

  • ENTA’s TA Score: 6 bullish, 4 bearish.
  • KRYS’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than ENTA.

Price Growth

ENTA (@Biotechnology) experienced а +16.88% price change this week, while KRYS (@Biotechnology) price change was +5.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

ENTA is expected to report earnings on Aug 11, 2025.

KRYS is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($3.84B) has a higher market cap than ENTA($154M). ENTA YTD gains are higher at: 25.217 vs. KRYS (-15.722). KRYS has higher annual earnings (EBITDA): 140M vs. ENTA (-94.42M). KRYS has more cash in the bank: 617M vs. ENTA (217M). KRYS has less debt than ENTA: KRYS (9.66M) vs ENTA (57.5M). KRYS has higher revenues than ENTA: KRYS (333M) vs ENTA (66.6M).
ENTAKRYSENTA / KRYS
Capitalization154M3.84B4%
EBITDA-94.42M140M-67%
Gain YTD25.217-15.722-160%
P/E RatioN/A31.83-
Revenue66.6M333M20%
Total Cash217M617M35%
Total Debt57.5M9.66M595%
FUNDAMENTALS RATINGS
ENTA vs KRYS: Fundamental Ratings
ENTA
KRYS
OUTLOOK RATING
1..100
94
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
10047
SMR RATING
1..100
9557
PRICE GROWTH RATING
1..100
5389
P/E GROWTH RATING
1..100
197
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (70) in the Pharmaceuticals Major industry is in the same range as ENTA (96) in the Biotechnology industry. This means that KRYS’s stock grew similarly to ENTA’s over the last 12 months.

KRYS's Profit vs Risk Rating (47) in the Pharmaceuticals Major industry is somewhat better than the same rating for ENTA (100) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than ENTA’s over the last 12 months.

KRYS's SMR Rating (57) in the Pharmaceuticals Major industry is somewhat better than the same rating for ENTA (95) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than ENTA’s over the last 12 months.

ENTA's Price Growth Rating (53) in the Biotechnology industry is somewhat better than the same rating for KRYS (89) in the Pharmaceuticals Major industry. This means that ENTA’s stock grew somewhat faster than KRYS’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for KRYS (97) in the Pharmaceuticals Major industry. This means that ENTA’s stock grew significantly faster than KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTAKRYS
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 15 days ago
84%
Bearish Trend 15 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NGRRX33.25N/A
N/A
Nuveen International Value I
BCLPX8.66N/A
N/A
BlackRock Event Driven Equity Inv C
GAAHX17.12N/A
N/A
GMO Resources R6
VVIEX12.32N/A
N/A
VOYA VACS Index Series EM Portfolio
CMRGX10.00-0.01
-0.10%
Calamos Merger Arbitrage I

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with ACLX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+0.86%
ACLX - KRYS
57%
Loosely correlated
+0.52%
IDYA - KRYS
56%
Loosely correlated
-2.50%
CGON - KRYS
54%
Loosely correlated
-0.78%
CRNX - KRYS
54%
Loosely correlated
+0.78%
XNCR - KRYS
53%
Loosely correlated
-0.44%
More